Expanding the Pool in Orthotopic Heart Transplantation: The Use of Hepatitis C Positive Donor Hearts in Hepatitis C Negative Recipients
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Adverse Events
研究概览
简要总结
This is an open-label, pilot trial to test the safety and efficacy of transplantation of hearts from HCV seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV Ab+/NAT+) donors to HCV seronegative recipients on the heart transplant waitlist. Treatment and prophylaxis will be administered, using a transmission-triggered approach for the first scenario (HCV Ab+/NAT- donors, arm 1) and a prophylaxis approach for the later scenario (HCV Ab+/NAT+ donors, arm 2).
详细描述
This is a prospective, single center, pilot, open-label study of transplantation of hearts of HCVAb+ donors to HCVAb- recipients with subsequent therapy with sofosbuvir/velpatasvir (Epclusa®). Recipients of a heart from HCVAb+/NAT- donors is ARM 1 or the transmission-triggered arm of the study. In this arm, the study will monitor transmission of HCV by measuring HCV RNA in heart transplant recipients. If HCV RNA is detected, indicating transmission of HCV, recipients will be treated with sofosbuvir/velpatasvir (Epclusa®) for 12 weeks. Virological response will be assessed at 4 weeks, end of treatment and 12 weeks after completion of therapy.
Recipients of a heart from HCVAb+/NAT+ donors will be in ARM 2 or the prophylaxis arm of the study. In this arm, patients will be started on a 12-week course of sofosbuvir/velpatasvir (Epclusa®) on post-operative day 1 and will undergo close monitoring of HCV RNA for evidence of transmission as well as monitoring of adverse events from therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 71 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(recipients):
- •End stage heart failure
- •Age ≥ 18 and <71 years
- •Listed heart transplant at UPMC
- •Have panel reactive antibody level of <98%
- •No obvious contraindication to liver transplant
- •Able to travel to UPMC for routine post-transplant visits and study visits for a minimum of 12 months after transplantation
- •Able to provide informed consent
- •Be willing to use a contraceptive method for a year after transplant
- •Inclusion criteria (donors):
- •HCV antibody positive
- •HCV NAT negative or positive
- •Acceptable cardiac function for donation
排除标准
- •(recipients):
- •HIV positive
- •HCVAb or HCV RNA positive
- •Presence of behavioral risk factors for contracting HCV. These behavioral risk factors are current injection drug use, current intranasal illicit drug use, current percutaneous/parenteral exposures in an unregulated setting.
- •Hepatitis B surface antigen positive
- •History of liver cirrhosis
- •Persistently elevated liver transaminases, defined as ALT/AST at least 3 times the upper limit of normal for a minimum of 3 consecutive months
- •Waitlisted for a multi-organ transplant
- •Pregnant women
- •Known allergy to sofosbuvir/velpatasvir
- •Any condition, psychiatric or physical, that in the opinion of the investigator would make it unsafe to proceed with transplantation or interfere with the ability of the subject to participate in the study
- •Ongoing therapy with amiodarone for atrial or ventricular arrhythmia Prescribed use of Amiodarone
- •Exclusion criteria (donors):
- •Confirmed HIV positive (positive HIV-1 antibody, positive HIV-2 antibody, positive p24 antigen and/or positive HIV NAT)
- •Confirmed HBV positive (positive hepatitis B surface antigen and/or HBV NAT) Known ongoing therapy for HCV
研究组 & 干预措施
HCV seropositive non-viremic (HCV Ab+/NAT-) donor
HCV seropositive non-viremic (HCV Ab+/NAT-) donor hearts to HCV seronegative recipients.
Heart recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.
Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
Intervention: Drug: sofosbuvir/velpatasvir
干预措施: sofosbuvir/velpatasvir (Drug)
HCV seropositive viremic (HCV Ab+/NAT+) donor
HCV seropositive viremic (HCV Ab+/NAT+) donor hearts to HCV seronegative recipients.
Starting post-operative day 1, heart recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
Intervention: Drug: sofosbuvir/velpatasvir
干预措施: sofosbuvir/velpatasvir (Drug)
结局指标
主要结局
Adverse Events
时间窗: 5 years
Rate of adverse events due to sofosbuvir/velpatasvir (Epclusa) in patients in each experimental group
HCV free at 1 year
时间窗: 1 year
Proportion of participants in each experimental group who are free of HCV at 1 year following transplantation
次要结局
- Transmission rate of HCV from HCVAb+/NAT- donors to HCVAb- recipients(5 years)
- All-cause mortality(5 years)
- Incidence of allograft rejection(5 years)
- Incidence of graft loss(5 years)
- Waitlist time after enrollment(5 years)
研究者
Mary E. Keebler, MD
Associate Professor
University of Pittsburgh